Henlius's gastric cancer drug meets phase 3 trial endpoint
PositiveFinancial Markets

Henlius has achieved a significant milestone with its gastric cancer drug, successfully meeting the endpoints of its phase 3 trial. This is a crucial step in the development of new treatments for gastric cancer, a disease that affects many people worldwide. The positive results not only highlight the potential of Henlius's drug but also bring hope to patients and families dealing with this challenging illness.
— Curated by the World Pulse Now AI Editorial System